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Case report
X-linked adrenal hypoplasia congenita caused by a mutation in NR0B1/DAX-1 is 
a rare inherited disorder. Patients with adrenal hypoplasia congenita are usually 
diagnosed with primary adrenal insufficiency in infancy or early childhood and 
present hypogonadotropic hypogonadism during adolescence. Our patient first 
presented with adrenal crisis at the age of 2 months, which was managed with 
glucocorticoids and mineralocorticoids. At the age of 17 years, testicular volumes of 
5 mL each and a stretched penile length of 4 cm were noted. A combined pituitary 
function test showed a peak luteinizing hormone level of 2.68 mIU/mL, testosterone 
13.5 ng/dL, confirming hypogonadotropic hypogonadism. After whole-exome 
sequencing, a new variant of DAX-1, c.881T>C (p.Leu294Pro), was found. He was 
diagnosed with X-linked adrenal hypoplasia congenita and then treated with 
human choriogonadotropin for the induction of spermatogenesis as well as with 
steroid replacement therapy.
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A new variant of DAX-1, c.881T>C (p.Leu294Pro) causing X-linked adrenal hypoplasia 
congenita was found. In this case, the disease etiology was unclear until a genetic analysis was 
performed. A correct and early diagnosis is important for long-term treatment.
Introduction
X-linked adrenal hypoplasia congenita (OMIM: 300200) caused by gene mutations in 
DAX-1 (dosage-sensitive sex reversal, adrenal hypoplasia critical region, on chromosome X, 
gene 1) is a rare inherited disorder of the adrenal gland.1,2) The DAX-1 gene, also known as 
the NR0B1 gene, is located on the short arm of the X chromosome and encodes an orphan 
nuclear hormone receptor. DAX-1 is expressed in the hypothalamus, pituitary gland, adrenal 
gland, and gonads. Accordingly, mutations in this gene result in adrenal insufficiency and 
hypogonadotropic hypogonadism and typically occur in males. Impaired spermatogenesis 
due to this mutation has also been observed. However, the severity and clinical phenotype can 
differ between patients.
Here, we report a case of adrenal hypoplasia congenita in a 17-year-old Korean boy with a 
novel mutation in the NR0B1/DAX-1 gene. Our patient's main clinical manifestations were 
adrenal insufficiency and hypogonadotropic hypogonadism.
Case report
A 2-month-old male presented with recurrent vomiting and poor oral intake with irritability. 
He was born via cesarean section at 41-week gestation and weighed 3.9 kg. There were no 
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complications during the perinatal period. The patient had 
no family history of chronic illness. On physical examination, 
the patient was dehydrated and showed hyperpigmentation 
throughout his body. This pigmentation first appeared 2 weeks 
after birth. The patient's blood pressure was 86/46 mmHg 
(<50th percentile), with a heart rate of 134 beats per minute 
and a respiratory rate of 30 breaths per minute. He was 41 cm 
tall (50th–75th percentile) with a weight of 6 kg (25th–50th 
percentile) and a body mass index of 14.43 kg/m2 (5th–10th 
percentile). Laboratory tests revealed hyponatremia (113 mmol/
L), hyperkalemia (8.0 mmol/L), elevated adrenocorticotropic 
hormone (ACTH, 7,207.3 pg/mL) and a relatively low level of 
cortisol (5.4 μg/dL), indicating primary adrenal insufficiency. 
Subsequently, the replacement of  hydrocortisone and 
fludrocortisone was commenced. Other initial results before 
treatment were as follows: 17-hydroxyprogesterone (17-OHP), 
0.44 ng/mL; serum aldosterone level, 14.2 ng/dL; and plasma 
renin activity, 0.26 ng/mL/hr. Other basal hormone levels 
were within normal ranges (Table 1). Additional studies were 
performed to evaluate the etiology of the patient's adrenal 
insufficiency. The result of the adrenal cortex antibody test 
was negative, and the result of a very long-chain fatty acid test 
for adrenoleukodystrophy was not remarkable. However, the 
adrenal glands were not delineated as observed using pelvic 
ultrasound images. The patient was transferred to another 
hospital to be closer to his place of residence.
When he was 17 years old, the patient visited our hospital 
again for evaluation of his small testes and penis. At that time, his 
height was 163.5 cm (5th–10th percentile), and his body weight 
was 70 kg (50th–75th percentile). On physical examination, 
both testes were 5 mL in volume, and his stretched penile length 
was 4 cm, indicating androgen deficiency. A chromosome 
study showed a normal male karyotype with 46, XY. In a 
human choriogonadotropin stimulation test, the stimulated 
testosterone to dihydrotestosterone ratio was 7.24, and the basal 
and stimulated testosterone levels were 13.5 ng/dL and 239.2 
ng/dL, respectively (Table 2). In an ACTH stimulation test, the 
peak cortisol level was below 0.4 µg/dL, indicating cortisol 
deficiency. The levels of 17-OHP and 17-hydroxypregenenolone 
were also lower than normal, a result that is not compatible with 
congenital adrenal hyperplasia due to 21-hydroxylase deficiency 
or 3β-hydroxysteroid dehydrogenase deficiency (Table 3). 
Genetic analysis did not identify any mutations in the StAR 
gene. In a combined pituitary function test, the peak luteinizing 
hormone level was 2.68 mIU/mL, and the testosterone level was 
13.5 ng/dL, consistent with hypogonadotropic hypogonadism. 
The cortisol level was uncheckable, and the peak growth 
hormone level was 7.09 ng/mL (Table 4).
Genetic analysis for identifying the cause of  adrenal 
insufficiency and hypogonadotropic hypogonadism using 
whole-exome sequencing showed a mutation in the DAX-1 gene. 
Whole-exome sequencing was performed using the TruSight 
One panel of 4,813 genes (Illumina, San Diego, CA, USA) to 
screen for pathological mutations. The newly discovered variant 
was c.881T>C (p.Leu294Pro), and this missense mutation was 
predicted to be deleterious by sorting intolerant from tolerant 
Table 1. Initial laboratory study findings at the age of 2 months
Variable Value Reference range
Sodium (mmol/L) 113 135.0–145.0
Potassium (mmol/L) 8.0 3.5–5.5
Glucose (mg/dL) 104 70–110
17-OH-progesterone (ng/mL) 0.44 <3
Renin (ng/mL/hr) 0.26 0.32–1.84
Aldosterone (ng/dL) 14.2 18.6–134.0
Cortisol (μg/dL) 5.4 6.7–22.6
ACTH (pg/mL) 7207.3 7.2–63.3
LH (mIU/mL) 1.7 0.02–7.0
FSH (mIU/mL) 9.7 0.24-14.2
Testosterone (ng/mL) 0.38 0.03-2.7
ACTH, adrenocorticotropic hormone; LH, luteinizing hormone; 
FSH, follicle­stimulating hormone.
Table 2. Patient's human choriogonadotropin stimulation test 
results at the age of 17 years
Variable Basal(normal range) After stimulation
Testosterone (ng/dL) 13.5 (249–836) 239.2 
5α-dihydrotestosterone (ng/mL) 0.05 0.33
Testosterone to dihydrotestosterone 2.7 7.24
Table 3. Patient's adrenocorticotropic hormone stimulation test 
results at the age of 17 years
Variable Basal(normal range) After stimulation
Progesterone (ng/mL) <0.02 (0.1–1.2) <0.02
Pregnenolone <0.1 (0.1–1.0) 0.19
Androstenedione <0.1 (0.48–1.82) <0.1
17-OH-Progesterone (ng/mL) <0.02 (0.59–3.44) <0.02
17α-OH-Pregenenolone (ng/
mL)
< 0.10 (0.1–4.0) < 0.10
DHEA (ng/mL) <0.50 (<6.6) <0.50
ACTH (pg/mL) 1,806 (7.2–63.3) >2,000
Cortisol (μg/dL) <0.4 (7.2–63.3) <0.4
17­OHP, 17­hydroxyprogesterone; DHEA, dehydroepiandro­
sterone; ACTH, adrenocorticotropic hormone.
Table 4. Patient's combined anterior pituitary function test 
results at the age of 17 years
Variable Basal(normal range) Peak
ACTH (pg/mL) 917 (7.2–63.3) >1,250
Cortisol (μg/dL) <0.4 (6.7–22.6) <0.4
Luteinizing hormone level (mIU/mL) 0.74 (1.2–103.3) 1.42
Follicle-stimulating hormone level (mIU/mL) 3.74 (1.79–22.51) 5.48
Testosterone (ng/mL) 0.13 (2.49–8.36) -
Free T4 level (ng/dL) 1.04 (0.7–1.48) -
Thyroid-stimulating hormone (μU/mL) 4.48 (0.35–4.94) <0.025
Growth hormone level (ng/mL) 0.2 (0–9.5) 7.09
Prolactin level (ng/mL) 28.1(3.34–26.72) 80.2
ACTH, adrenocorticotropic hormone.
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(SIFT)3) and as probably damaging by PolyPhen-2.4) The variant 
was not found in ExAC (http://exac.broadinstitute.org/), Clin 
Var (http://www.ncbi.nlm.gov/clinvar/), nor dbSNP (http://
www.ncbi.nlm.nih.gov/project/SNP). Genetic analysis was 
not performed for the patient's family because they refused to 
give a blood sample. The diagnosis was confirmed as adrenal 
hypoplasia congenita. To induce spermatogenesis, exogenous 
human choriogonadotropin together with follicle-stimulating 
hormone were prescribed, as well as the existing hydrocortisone 
and fludrocortisone replacement.
Discussion
X-linked adrenal hypoplasia congenita is a rare inherited 
disease caused by mutations in the NR0B1/DAX-1 gene. 
The estimated incidence of NR0B1-related X-linked adrenal 
hypoplasia congenita in the general population is very low 
(1:70,000-1:1,2000,000).5,6) No specific populations are 
known to be at risk for this disorder. DAX-1 is expressed 
throughout the hypothalamo-pituitary-gonadal and adrenal 
axes and plays an important role in the development of these 
endocrine organs.7) Animal studies using DAX-1 knockout 
mice have shown progressive adrenal insufficiency to be a 
consequence of the loss of its function. Li et al.8) demonstrated 
a reduction in gonadotropin-releasing hormone expression 
in DAX-1 mutants using a luciferase assay. In addition, DAX-
1 knockout mice showed altered testicular architecture and 
impaired spermatogenesis.9) However, normal function 
of the hypothalamic-gonadotrope-Leydig cell axis during 
the minipuberty of infancy with this disease was reported; 
therefore, abnormalities in this axis may develop later in 
life.10,11) In adrenal hypoplasia congenita, the production of 
pituitary hormones other than gonadotropins is intact, but a 
low peak level of growth hormone was observed in our patient. 
This could be explained by inadequate sex hormone priming 
before the combined pituitary function test. Most patients with 
X-linked adrenal hypoplasia congenita present with symptoms 
of  adrenal insufficiency in infancy or early childhood, 
including skin pigmentation, hypoglycemia, salt wasting 
dehydration, and failure to thrive.5) In our patient, the clinical 
manifestations of adrenal insufficiency were noted before the 
age of 2 months, and glucocorticoid and mineralocorticoid 
replacement was initiated at the time of diagnosis of primary 
adrenal insufficiency. In late-onset X-linked adrenal hypoplasia 
congenita, these signs may first present in adulthood, and in 
such cases, the clinical phenotype is mild.7) The differential 
diagnosis of salt-losing primary adrenal insufficiency in male 
patients includes congenital adrenal hyperplasia, such as 
21-hydroxylase deficiency, congenital adrenal lipoid hyperplasia 
and 3β-hydroxysteroid dehydrogenase deficiency. In adrenal 
hypoplasia congenita, the adrenal glands lack the adult cortical 
zone, while they have a normal fetal adrenal cortex, and 
consequently show normal external male genitalia. In addition, 
they show different modes of inheritance and have normal or 
low levels of cortisol precursors, such as 17-OHP.
Patients with adrenal hypoplasia congenita may present 
entirely absent or arrested pubertal development because 
of  hypogonadotropic hypogonadism. The attainment of 
secondary sexual characteristics is achieved with testosterone 
replacement. However, they usually show impaired fertility 
due to azoospermia or oligospermia despite treatment with 
gonadotropin therapy.9) Interestingly, precocious puberty has 
also been reported in adrenal hypoplasia congenita patients 
with DAX-1 mutations in rare cases.12-14) In gonadotropin-
independent precocious puberty, high ACTH levels may 
stimulate the Leydig cells. However, the mechanism of 
precocity remains unclear, especially in patients with central 
precocious puberty. In heterozygous females, delayed puberty or 
adrenal insufficiency can sometimes occur because of skewed 
X-inactivation.
In the present case, targeted exome sequencing revealed a 
missense mutation (c.881T>C, p.L294P) in NR0B1 located 
in the putative ligand-binding domain, which has not been 
previously reported, although a similar mutation was found 
in Japan.15) A likely pathogenic variant according to the 
American College of Medical Genetics and Genomics guideline 
was discovered and predicted to be damaging by SIFT and 
Polyphen-2, and clinical manifestations were compatible with 
X-linked adrenal hypoplasia congenital.16) Most missense 
mutations of the DAX-1 gene are in the ligand-binding domain, 
as in this case. We hypothesize that this change altered the 
function of the protein, as the ligand-binding domain is a 
crucial region, but its function must be further validated in the 
future.
In conclusion, we report a novel mutation in the NR0B1/
DAX-1 gene in a patient with adrenal hypoplasia congenita. 
Our patient was first diagnosed with adrenal insufficiency at 
the age of 2 months, and he later manifested the absence of 
sexual characteristics. Although hormonal tests were performed, 
the disease etiology was unclear until a genetic analysis was 
performed. Because a correct and early diagnosis is important 
for long-term treatment in terms of endocrine and reproductive 
function and genetic counseling, the possibility of a DAX-
1 mutation must be considered in male patients with adrenal 
insufficiency if  a genetic diagnosis has not been reached. 
Monitoring pubertal development during follow-up is also 
helpful.
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